NCT03703375 2024-07-08Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgenePhase 3 Active not recruiting93 enrolled 19 charts
NCT01232556 2019-01-08A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyPfizerPhase 3 Terminated338 enrolled 15 charts
NCT00920153 2016-09-16Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin LymphomaFrench Innovative Leukemia OrganisationPhase 3 Terminated442 enrolled